Havana, May 30 (RHC)-- The Group of Biotechnological and Pharmaceutical Industries of Cuba (BioCubaFarma) is advancing today a strategy aimed at producing 525 medications amid the limitations imposed by the U.S. economic blockade.

"The sector is working tirelessly to guarantee 525 of the 849 medicines in the basic list of the National Health System," said BioCubaFarma's president, Eduardo Martínez.

This effort - Granma newspaper reported - is being carried out amid limitations in the availability of raw materials derived from the intensification of the economic, commercial, and financial blockade imposed by the United States against Cuba.

The National Medicines Program's premise is to ensure the availability of medicines for the health of our people and the development and introduction of innovative products and technologies that allow for an increase in exports.

This scheme was conceived on five pillars: the replacement of imports, the strengthening of the Biopharmaceutical Industry, the application of the Natural and Traditional Medicine program, and the development of pharmaceutical services and Pharmacoepidemiology.